These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9676845

  • 21. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G, Lelli G.
    Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
    [Abstract] [Full Text] [Related]

  • 22. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 23. Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.
    Aydiner A, Koyuncu H, Tas F, Topuz E, Disci R.
    Int J Clin Pharmacol Res; 2000 May 15; 20(1-2):21-30. PubMed ID: 11146899
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer.
    Miller AA, Tolley EA, Niell HB, Stewart CF, Griffin JP.
    Cancer Chemother Pharmacol; 1992 May 15; 31(2):161-6. PubMed ID: 1333371
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Correlation between an enzyme (glutathione S-transferase-pi) and effects of chemotherapy (cisplatin + etoposide)].
    Arai T, Yasuda Y, Ito Y, Hayakawa K, Takaya T, Toshima S, Shibuya C, Nawada M, Shibayama M, Yoshimi N, Ito H, Fujiwara H.
    Gan To Kagaku Ryoho; 1996 Jun 15; 23(7):881-5. PubMed ID: 8678536
    [Abstract] [Full Text] [Related]

  • 29. [Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
    Hayasaka S, Kinuwaki E, Nakabayashi T, Saito R, Komatsu H, Nishikawa H, Ohizumi K, Shimizu T, Nakai Y, Niitani H.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Dec 15; 33(12):1367-1371. PubMed ID: 8821989
    [Abstract] [Full Text] [Related]

  • 30. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
    Minami H, Ando Y, Sakai S, Shimokata K.
    J Clin Oncol; 1995 Jan 15; 13(1):191-9. PubMed ID: 7799020
    [Abstract] [Full Text] [Related]

  • 31. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
    Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA.
    J Clin Oncol; 1992 Feb 15; 10(2):292-6. PubMed ID: 1310104
    [Abstract] [Full Text] [Related]

  • 32. [Pharmacokinetic study and side effects of chronic daily administration of oral etoposide].
    Taguchi O, Yamakami T, Machishi M, Gabazza EC, Ibata H, Tsutsui K, Suzuki S.
    Gan To Kagaku Ryoho; 1992 Oct 15; 19(12):2005-9. PubMed ID: 1329670
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma.
    Higa GM, Sarkar MA, DeVore RF.
    Pharmacotherapy; 1999 Jan 15; 19(1):101-7. PubMed ID: 9917083
    [Abstract] [Full Text] [Related]

  • 34. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL, Kaubisch S, Fisher GA, Brown BW, Sikic BI.
    Cancer Chemother Pharmacol; 2000 Jan 15; 45(4):305-11. PubMed ID: 10755319
    [Abstract] [Full Text] [Related]

  • 35. Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
    Gerritsen-van Schieveen P, Royer B, Therapeutic Drug Monitoring Group of the French Society of Pharmacology and Therapeutics.
    Fundam Clin Pharmacol; 2011 Jun 15; 25(3):277-82. PubMed ID: 20608987
    [Abstract] [Full Text] [Related]

  • 36. Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer.
    Miller AA, Niell HB, Griffin JP.
    Lung Cancer; 1995 Mar 15; 12(1-2):59-65. PubMed ID: 7600031
    [Abstract] [Full Text] [Related]

  • 37. Validation of a limited sampling model to determine etoposide area under the curve.
    Lum BL, Lane KJ, Synold TW, Goram A, Charnick SB, Sikic BI.
    Pharmacotherapy; 1997 Mar 15; 17(5):887-90. PubMed ID: 9324178
    [Abstract] [Full Text] [Related]

  • 38. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.
    Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M.
    J Clin Oncol; 1996 Jun 15; 14(6):1903-12. PubMed ID: 8656259
    [Abstract] [Full Text] [Related]

  • 39. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
    Sprinz E, Caldas AP, Mans DR, Cancela A, DiLeone L, Dalla Costa T, Schwartsmann G.
    Am J Clin Oncol; 2001 Apr 15; 24(2):177-84. PubMed ID: 11319295
    [Abstract] [Full Text] [Related]

  • 40. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F, Chen S, Miller AA, Lee BC, Molthrop DC, Wheeler RH.
    Cancer Chemother Pharmacol; 1996 Apr 15; 38(5):459-65. PubMed ID: 8765440
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.